Granite Point Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Granite Point Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-129,167	Closed	-$1.37M	–	118
2019 Q1	$1.37M	Buy	+129,167	New	+$1.29M	0.13%	56
2018 Q3	–	Sell	-12,500	Closed	-$226K	–	147
2018 Q2	$226K	Buy	12,500 +4,722	+61%	+$69.6K	0.02%	110
2018 Q1	$83K	Buy	+7,778	New	+$125K	0.01%	107

Other funds holding SIOX

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Granite Point Capital Management's SIOX Position: Q2 2019 in Review

Granite Point Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2019, closing a stake of 129,167 shares — an estimated $1.37M sold.

Granite Point Capital Management first reported a position in SIOX in Q1 2018 and held it in 3 quarters. The position peaked at $1.37M in Q1 2019. 39 funds tracked by Wall St. Rank hold SIOX as of Q2 2019.

Granite Point Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Granite Point Capital Management sold 129,167 Sio Gene Therapies Inc. Common Stock shares in Q2 2019, an estimated $1.37M.
Granite Point Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Granite Point Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.37M in Q1 2019.
39 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2019.

Based on Granite Point Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.